For the quarter ending 2025-09-30, MTNB had -$1,090K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,532 | -6,901 |
| Depreciation and amortization | -1 | 30 |
| Gain on sale of assets | 0 | 110 |
| Stock based compensation expense | 253 | 553 |
| Change in operating lease right-of-use assets | 111 | 218 |
| Amortization of bond discount | - | 0 |
| Change in finance lease right-of-use assets | 1 | 2 |
| Change in fair value of warrant liability | 0 | 3,161 |
| Operating lease liabilities | -195 | -363 |
| Prepaid expenses and other current assets | -205 | -319 |
| Accounts payable | -86 | 71 |
| Accrued expenses and other liabilities | -230 | -1,008 |
| Net cash used in operating activities | -1,474 | -4,028 |
| Proceeds from maturities of marketable debt securities | - | 0 |
| Purchase of marketable debt securities | - | 0 |
| Proceeds from sale of assets | 320 | - |
| Net cash provided by investing activities | 320 | 0 |
| Gross proceeds from private placement of preferred stock and common stock warrants | 0 | 3,300 |
| Net proceeds from public offering of common stock and warrants | - | 0 |
| Transaction costs paid pursuant to private placement | 0 | 29 |
| Net proceeds from exercise of warrants | 64 | - |
| Payments of finance lease liability principal | 0 | 2 |
| Net cash provided by financing activities | 64 | 3,269 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | -1,090 | -759 |
| Cash and cash equivalents at beginning of period | 7,534 | - |
| Cash and cash equivalents at end of period | 5,685 | - |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)